HomeNewsPodcastSetting Sail season 2, Ep. 1 | What demonetisation did to e-payments, COVID-19 will do to e-healthcare: Medlife CEO

Setting Sail season 2, Ep. 1 | What demonetisation did to e-payments, COVID-19 will do to e-healthcare: Medlife CEO

Ananth Narayanan, co-founder and CEO of Medlife, talks about what's happening in the healthcare business in these times

August 18, 2020 / 22:01 IST
Story continues below Advertisement

The Setting Sail podcast is back with a second season, where Moneycontrol's Special Correspondent Priyanka Sahay talks to entrepreneurs and CEOs to learn about their strategies to combat the COVID-19 crisis.
In this maiden episode, Sahay gets in conversation with Ananth Narayanan, co-founder and CEO of Medlife, to get a glimpse of what's happening in the healthcare business in these times.
Tune in to the Setting Sail podcast for more.
You can also find the transcript of the podcast below:
Priyanka Sahay: Unprecedented situations demand unprecedented action. At a time when COVID-19 has literally brought the country to a standstill, domestic startups are trying their best to innovate and survive the crisis. But the question is, how will they manage to reacquire the lost market share at a time when the consumer pattern and the way business was done is about to change completely.

Hello, welcome to Moneycontrol. This is Priyanka Sahay, special correspondent. And you are tuned in to Setting Sail, our weekly podcast that dives through the changing landscape of the entrepreneurship ecosystem and the challenges within.

Well, I would like to welcome Ananth Narayananan, Co-Founder and Chief Executive Officer of healthcare startup Medlife. And who's also been the Chief Executive of Flipkart-owned fashion website Myntra, with us today.

Story continues below Advertisement

Hi, Ananth, thank you so much for joining in.

Ananth Narayanan: Thank you for having me, Priyanka.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show